MaterialRefer to Web version on PubMed Central for supplementary material.AcknowledgmentsWe thank our colleagues, in particular Larry Marnett (Vanderbilt) for precious discussions and/or careful reading on the manuscript. We’re indebted to Dr. Frank J Gonzalez for sharing his Cyp1b1(?? knockout line much more than a decade ago, which has helped immensely in our combined-knockout mouse breeding research. Grant Assistance: This project was funded by Cystic Fibrosis Foundation RDP Center Element II Grant (C.L.K.), National Institutes of Basic Medical Sciences [Grant P01 GM095467] (C.N.S.), and National Institute of Environmental Wellness Sciences [Grant T32 ES016646] (M.G.-P.), and [Grants R01 ES008147, R01 ES014403 and P30 ES06096] (D.W.N.).Abbreviations usedAA Cyp1 CYP1A1/CYP1A2/ CYP1B1 Cyp1a1, Cyp1a2, Cyp1b1 DHA EPA EPI ETEs GC-MS/MS HpDHAs HpETEs HDHA HEPEs HETEs HpEPEs LC/HPLC LC-UV LC-UV-MS/MS LTA4, LTB4 arachidonic acid cytochrome P450 1 gene family members encoding 3 enzymes cytochrome P450 1A1/1A2/1B1 mRNA protein cytochrome P450 (loved ones 1) genes in mouse docosahexaenoic acid eicosapentaenoic acid enhanced item ion eicosatetraenoic acids gas chromatography coupled with tandem mass spectrometry hydroperoxydocosahexenoic acids hydroperoxyeicosatetraenoic acids hydroxydocosahexenoic acids hydroxyeicosapentaenoic acids hydroxyeicosatetraenoic acids hydroperoxyeicosapentaenoic acids high-performance liquid chromatography liquid chromatography-UV spectrometry liquid chromatography-UV coupled with tandem mass spectrometry leukotrienes A4, BJ Immunol.368866-07-3 Chemical name Author manuscript; out there in PMC 2014 September 15.138099-40-8 Chemscene Divanovic et al.PageLXA4, LXBlipoxins A4, B4 Maresin (macrophage mediators in resolving inflammation, dihydroxydocosahexaenoic acid) multiple-reaction monitoring neuroprotectin/protectin D1 prostaglandins H2, D2, E2, F2 prostaglandin G synthase-2 (inducible cyclooxygenase-2; COX2) resolvins E1, E2. D1, D2, D3, D4, D5, DNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptMaR1 MRM PD1 or [N]PD1 PGH2, PGD2, PGE2, PGF2?PTGS2 RvE1, RvE2, RvD1, RvD2, RvD3, RvD4, RvD5, RvD6 TxA2, TxB2 TKO TOF WTthromboxanes A2, BCyp1a1/1a2/1b1(?? triple-knockout on 99.8 C57BL/6J backgroundtime-of-flight, utilized to establish mass-to-charge (m/z) ratio in mass spectrometer C57BL/6J wild-type mouse
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL.PMID:35991869 289, NO. 34, pp. 23343?3352, August 22, 2014 ?2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.Functional Effects of a Pathogenic Mutation in Cereblon (CRBN) on the Regulation of Protein Synthesis via the AMPK-mTOR Cascade*Received for publication, October 1, 2013, and in revised type, June 29, 2014 Published, JBC Papers in Press, July 3, 2014, DOI ten.1074/jbc.M113.Kwang Min Lee1, Seung-Joo Yang, Ja-Hyun Choi, and Chul-Seung Park2 From the College of Life Sciences, Cell Dynamics Study Center and National Leading Analysis Laboratory, Gwangju Institute Science and Technology (GIST), Gwangju, 500-712, The Republic of KoreaBackground: Deficiency or nonsense mutation of CRBN causes memory deficits. Benefits: Truncated CRBN has insufficient affinity for AMPK and can’t modulate the AMPK-mTOR pathway. Conclusion: CRBN modulates protein synthesis by means of the AMPK-mTOR pathway, and may possibly be vital for certain forms of memory encoding. Significance: Our findings suggest the initial plausible mechanism for the phenotype resulting from the CRBN mutation. Initially identified as a pr.